查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1957527

2026年全球寡核苷酸疗法市场报告

Oligonucleotide Therapy Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，寡核苷酸疗法市场发展迅速。预计该市场将从2025年的62亿美元成长到2026年的69.1亿美元，复合年增长率（CAGR）为11.5%。过去几年的成长主要归功于寡核苷酸合成领域研发的加强、标靶治疗需求的成长、分子生物学技术的进步、慢性病和遗传性疾病的增加，以及反义寡核苷酸和适配体技术的早期应用。

预计未来几年寡核苷酸疗法市场将快速成长，到2030年将达到108.7亿美元，复合年增长率（CAGR）为12.0%。预测期内的成长要素包括个人化医疗的扩展、人工智慧（AI）在药物研发中的应用、精准医疗倡议的推进、新一代递送平台的开发以及生物技术公司与製药公司之间合作的加强。预测期内的关键趋势包括标靶基因调控、基于RNA干扰（RNAi）的治疗方法、个人化医疗的发展、先进的药物传递系统以及基于核酸的诊断技术。

政府支持医疗领域研发的各项措施预计将推动寡核苷酸疗法市场的成长。这些措施包括政府机构在地方、区域、国家和国际层面实施的项目、政策和计划，旨在应对特定的医疗挑战、实现目标并促进社会变革。多个国家的政府正在采取措施支持寡核苷酸疗法的各个方面。例如，根据美国医学会（AMA）——一家总部位于美国的专业组织——的数据显示，截至2025年4月，美国医疗保健支出在2023年达到4.9万亿美元（人均14,570美元），比上年增长7.5%，超过了2022年4.6%的增幅。因此，政府主导的医疗研发投资正在推动寡核苷酸疗法市场的成长。

寡核苷酸疗法市场的主要企业正在开发先进治疗方法，例如基因疗法，旨在解决遗传疾病的根本原因，改善患者预后，并减轻长期治疗负担。基因疗法是治疗方法。例如，2023年6月，美国生物技术公司Sarepta Therapeutics Inc.的ELEVIDYS获得FDA核准，这是全球首个用于治疗Duchenne氏肌肉失养症（DMD）儿童的基因治疗药物。这种单剂量疗法旨在透过将编码缩短的功能性肌肉营养不良蛋白的基因导入儿童细胞来阻止或逆转疾病进展。

目录

第一章：执行摘要

第二章 市场特征

  • 市场定义和范围
  • 市场区隔
  • 主要产品和服务概述
  • 全球寡核苷酸疗法市场：吸引力评分及分析
  • 成长可能性分析、竞合评価、戦略适合性评価、リスクプロファイル评価

第三章 市场供应链分析

  • 供应链与生态系概述
  • 清单：主要原料、资源和供应商
  • 主要经销商和通路合作伙伴名单
  • 主要最终用户列表

第四章：全球市场趋势与策略

  • 关键科技与未来趋势
    • 生物技术、基因组学和精准医疗
    • 数位化、云端运算、巨量资料、网路安全
    • 工业4.0和智慧製造
    • 人工智慧（AI）和自主人工智慧
    • 物联网、智慧基础设施、互联生态系统
  • 主要趋势
    • 标靶基因调控
    • 基于RNA干扰的治疗方法
    • 个性化医疗的发展
    • 先进的药物传输系统
    • 基于核酸的诊断

第五章 终端用户产业市场分析

  • 医院
  • 研究机构
  • 製药公司
  • 生技公司
  • 学术机构

第六章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税的影响、关税战和贸易保护主义对供应链的影响，以及 COVID-19 疫情对市场的影响。

第七章：全球策略分析架构、目前市场规模、市场对比及成长率分析

  • 全球寡核苷酸疗法市场：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 全球寡核苷酸疗法市场规模、对比及成长率分析
  • 全球寡核苷酸疗法市场表现：规模与成长，2020-2025年
  • 全球寡核苷酸疗法市场预测：规模与成长，2025-2030年，2035年预测

第八章：全球市场总规模（TAM）

第九章 市场细分

  • 按类型
  • 反义寡核苷酸、适体和其他类型
  • 透过使用
  • 感染疾病、肿瘤、神经退化性疾病、心血管疾病、肾臟疾病和其他最终用户
  • 最终用户
  • 医院、研究机构
  • 按类型细分：反义寡核苷酸
  • RNA标靶反义寡核苷酸、DNA标靶反义寡核苷酸、化学修饰的反义寡核苷酸
  • 按类型细分：适体
  • DNA适体、RNA适体、低分子量适体
  • 按类型细分：其他类型
  • siRNA（小干扰RNA）、miRNA（微型RNA）、DNA酶和核糖酶、用于基因编辑的合成寡核苷酸

第十章 区域与国别分析

  • 全球寡核苷酸疗法市场：按地区划分，实际结果和预测，2020-2025年，2025-2030年预测，2035年预测
  • 全球寡核苷酸疗法市场：按国家/地区划分，实际结果和预测，2020-2025 年、2025-2030 年预测、2035 年预测

第十一章 亚太市场

第十二章：中国市场

第十三章：印度市场

第十四章：日本市场

第十五章：澳洲市场

第十六章：印尼市场

第十七章：韩国市场

第十八章 台湾市场

第十九章 东南亚市场

第20章 西欧市场

第21章英国市场

第22章：德国市场

第23章：法国市场

第24章：义大利市场

第25章：西班牙市场

第26章：东欧市场

第27章：俄罗斯市场

第28章 北美市场

第29章：美国市场

第三十章：加拿大市场

第31章：南美市场

第32章：巴西市场

第33章 中东市场

第34章：非洲市场

第三十五章 市场监理与投资环境

第36章：竞争格局与公司概况

  • 寡核苷酸疗法市场：竞争格局及市场占有率（2024年）
  • 寡核苷酸疗法市场：公司评估矩阵
  • 寡核苷酸疗法市场：公司概况
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Gilead Sciences Inc.
    • Biogen Inc.
    • Alnylam Pharmaceuticals Inc.

第37章 其他大型企业和创新企业

  • Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Avidity Biosciences Inc., Miragen Therapeutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies BV

第38章 世界の市场竞合ベンチマーキングとダッシュボード

第39章 重大併购

第四十章：高潜力市场国家、细分市场与策略

  • 2030年寡核苷酸疗法市场：提供新机会的国家
  • 2030年寡核苷酸疗法市场：蕴藏新机会的细分市场
  • オリゴヌクレオチド治疗市场2030：成长戦略
    • 基于市场趋势的策略
    • 竞争对手的策略

第41章附录

简介目录
Product Code: PH3MOTHE02_G26Q1

Oligonucleotide therapy is a term for advanced molecular-targeting treatments that use chemically synthesized oligonucleotides with single-stranded DNA or RNA backbones, offering high selectivity. Oligonucleotides are designed to base-pair with specific DNA or RNA strands for most applications, with PCR primers being the most common use of oligonucleotides (polymerase chain reaction).

The main types of oligonucleotide therapy include antisense oligonucleotides, aptamers, and others. Antisense oligonucleotides (ASOs) are synthetic DNA oligomers that bind to a target RNA in a sequence-specific manner. They are used to inhibit gene expression, modify precursor messenger RNA splicing, and inactivate microRNAs. Oligonucleotide therapies are applied in infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases, and other conditions, and are utilized in hospitals and research institutes.

Tariffs have affected the oligonucleotide therapy market by increasing costs of imported nucleotides, reagents, and specialized synthesis equipment, causing delays in production and supply chains. The impact is particularly notable in segments such as antisense oligonucleotides and aptamers, with North America, Europe, and Asia-Pacific being most affected due to high import dependencies. Some positive impacts include incentivizing local manufacturing and fostering innovation in cost-effective oligonucleotide synthesis and delivery solutions.

The oligonucleotide therapy market research report is one of a series of new reports from The Business Research Company that provides oligonucleotide therapy market statistics, including oligonucleotide therapy industry global market size, regional shares, competitors with a oligonucleotide therapy market share, detailed oligonucleotide therapy market segments, market trends and opportunities, and any further data you may need to thrive in the oligonucleotide therapy industry. This oligonucleotide therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oligonucleotide therapy market size has grown rapidly in recent years. It will grow from $6.2 billion in 2025 to $6.91 billion in 2026 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to increasing r&d in oligonucleotide synthesis, growing demand for targeted therapies, advances in molecular biology techniques, rise in chronic and genetic diseases, early adoption of antisense and aptamer technologies.

The oligonucleotide therapy market size is expected to see rapid growth in the next few years. It will grow to $10.87 billion in 2030 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to expansion of personalized medicine, integration of ai in drug discovery, growth of precision medicine initiatives, development of next-gen delivery platforms, increasing partnerships between biotech and pharma companies. Major trends in the forecast period include targeted gene regulation, rna interference-based therapeutics, personalized medicine development, advanced drug delivery systems, nucleic acid-based diagnostics.

Government initiatives supporting research and development in healthcare are expected to drive growth in the oligonucleotide therapy market. Such initiatives encompass programs, policies, and projects undertaken by government authorities at local, regional, national, or international levels to address specific healthcare challenges, achieve objectives, and promote positive societal change. Several governments are implementing initiatives that support various aspects of oligonucleotide therapy. For instance, in April 2025, according to the American Medical Association, a US-based professional organization, U.S. health spending in 2023 rose by 7.5% to $4.9 trillion, or $14,570 per capita, surpassing the 4.6% increase seen in 2022. These government-led investments in healthcare research and development are therefore driving growth in the oligonucleotide therapy market.

Leading companies in the oligonucleotide therapy market are developing advanced treatments, such as gene therapies, to target the root causes of genetic diseases, improve patient outcomes, and reduce long-term treatment burdens. Gene therapies involve introducing a functional gene into a patient's cells to replace a non-functional or mutated gene. For example, in June 2023, Sarepta Therapeutics Inc., a US-based biotechnology company, received FDA approval for ELEVIDYS, a first-of-its-kind gene therapy for ambulatory pediatric patients with Duchenne muscular dystrophy (DMD). This single-dose treatment delivers a gene coding for a shortened functional form of dystrophin to muscle cells, aiming to halt or reverse disease progression.

In April 2025, AlphaRose Therapeutics, a US-based biopharmaceutical company, acquired Alpha Anomeric SA for an undisclosed amount. This acquisition enables AlphaRose Therapeutics to strengthen its oligonucleotide therapeutics portfolio, accelerate innovation in gene-targeted therapies, expand R&D capabilities, and enhance its competitive position in the global nucleic acid therapeutics market. Alpha Anomeric SA is a France-based company specializing in oligonucleotide therapies.

Major companies operating in the oligonucleotide therapy market are Pfizer Inc., GlaxoSmithKline plc, Gilead Sciences Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Avidity Biosciences Inc., Miragen Therapeutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V., Evox Therapeutics Ltd., PepGen Ltd.

North America was the largest region in the oligonucleotide therapy market in 2025. The regions covered in the oligonucleotide therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oligonucleotide therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oligonucleotide therapy market consists of sales of ASOs, siRNAs, miRNAs, and DNAzymes. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oligonucleotide Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses oligonucleotide therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oligonucleotide therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oligonucleotide therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Type: Antisense Oligonucleotide; Aptamer; Other Types
  • 2) By Application: Infectious Diseases; Oncology; Neurodegenerative Disorders; Cardiovascular Diseases; Kidney Diseases; Other End-User
  • 3) By End User: Hospitals; Research Institutes
  • Subsegments:
  • 1) By Antisense Oligonucleotide: RNA-Targeted Antisense Oligonucleotides; DNA-Targeted Antisense Oligonucleotides; Chemically Modified Antisense Oligonucleotides
  • 2) By Aptamer: DNA Aptamers; RNA Aptamers; Small Molecule Aptamers
  • 3) By Other Types: siRNA (Small Interfering RNA); miRNA (Micro RNA); DNAzyme And Ribozymes; Synthetic Oligonucleotides For Gene Editing
  • Companies Mentioned: Pfizer Inc.; GlaxoSmithKline plc; Gilead Sciences Inc.; Biogen Inc.; Alnylam Pharmaceuticals Inc.; Sarepta Therapeutics Inc.; Ionis Pharmaceuticals Inc.; Akcea Therapeutics Inc.; Arrowhead Pharmaceuticals Inc.; Dicerna Pharmaceuticals Inc.; SomaGenics Inc.; Wave Life Sciences Ltd.; Exicure Inc.; Avidity Biosciences Inc.; Miragen Therapeutics Inc.; ProQR Therapeutics NV; Regulus Therapeutics Inc.; Kastle Therapeutics LLC; Santaris Pharma A/S; InteRNA Technologies B.V.; Evox Therapeutics Ltd.; PepGen Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Oligonucleotide Therapy Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Oligonucleotide Therapy Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Oligonucleotide Therapy Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Oligonucleotide Therapy Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.3 Industry 4.0 & Intelligent Manufacturing
    • 4.1.4 Artificial Intelligence & Autonomous Intelligence
    • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Targeted Gene Regulation
    • 4.2.2 Rna Interference-Based Therapeutics
    • 4.2.3 Personalized Medicine Development
    • 4.2.4 Advanced Drug Delivery Systems
    • 4.2.5 Nucleic Acid-Based Diagnostics

5. Oligonucleotide Therapy Market Analysis Of End Use Industries

  • 5.1 Hospitals
  • 5.2 Research Institutes
  • 5.3 Pharmaceutical Companies
  • 5.4 Biotechnology Firms
  • 5.5 Academic Institutions

6. Oligonucleotide Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Oligonucleotide Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Oligonucleotide Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Oligonucleotide Therapy Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Oligonucleotide Therapy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Oligonucleotide Therapy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Oligonucleotide Therapy Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Oligonucleotide Therapy Market Segmentation

  • 9.1. Global Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Antisense Oligonucleotide, Aptamer, Other Types
  • 9.2. Global Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Other End-User
  • 9.3. Global Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospitals, Research Institutes
  • 9.4. Global Oligonucleotide Therapy Market, Sub-Segmentation Of Antisense Oligonucleotide, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • RNA-Targeted Antisense Oligonucleotides, DNA-Targeted Antisense Oligonucleotides, Chemically Modified Antisense Oligonucleotides
  • 9.5. Global Oligonucleotide Therapy Market, Sub-Segmentation Of Aptamer, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • DNA Aptamers, RNA Aptamers, Small Molecule Aptamers
  • 9.6. Global Oligonucleotide Therapy Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • siRNA (Small Interfering RNA), miRNA (Micro RNA), DNAzyme And Ribozymes, Synthetic Oligonucleotides For Gene Editing

10. Oligonucleotide Therapy Market Regional And Country Analysis

  • 10.1. Global Oligonucleotide Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Oligonucleotide Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Oligonucleotide Therapy Market

  • 11.1. Asia-Pacific Oligonucleotide Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Oligonucleotide Therapy Market

  • 12.1. China Oligonucleotide Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Oligonucleotide Therapy Market

  • 13.1. India Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Oligonucleotide Therapy Market

  • 14.1. Japan Oligonucleotide Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Oligonucleotide Therapy Market

  • 15.1. Australia Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Oligonucleotide Therapy Market

  • 16.1. Indonesia Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Oligonucleotide Therapy Market

  • 17.1. South Korea Oligonucleotide Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Oligonucleotide Therapy Market

  • 18.1. Taiwan Oligonucleotide Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Oligonucleotide Therapy Market

  • 19.1. South East Asia Oligonucleotide Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Oligonucleotide Therapy Market

  • 20.1. Western Europe Oligonucleotide Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Oligonucleotide Therapy Market

  • 21.1. UK Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Oligonucleotide Therapy Market

  • 22.1. Germany Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Oligonucleotide Therapy Market

  • 23.1. France Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Oligonucleotide Therapy Market

  • 24.1. Italy Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Oligonucleotide Therapy Market

  • 25.1. Spain Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Oligonucleotide Therapy Market

  • 26.1. Eastern Europe Oligonucleotide Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Oligonucleotide Therapy Market

  • 27.1. Russia Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Oligonucleotide Therapy Market

  • 28.1. North America Oligonucleotide Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Oligonucleotide Therapy Market

  • 29.1. USA Oligonucleotide Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Oligonucleotide Therapy Market

  • 30.1. Canada Oligonucleotide Therapy Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Oligonucleotide Therapy Market

  • 31.1. South America Oligonucleotide Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Oligonucleotide Therapy Market

  • 32.1. Brazil Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Oligonucleotide Therapy Market

  • 33.1. Middle East Oligonucleotide Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Oligonucleotide Therapy Market

  • 34.1. Africa Oligonucleotide Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Oligonucleotide Therapy Market Regulatory and Investment Landscape

36. Oligonucleotide Therapy Market Competitive Landscape And Company Profiles

  • 36.1. Oligonucleotide Therapy Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Oligonucleotide Therapy Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Oligonucleotide Therapy Market Company Profiles
    • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Alnylam Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Oligonucleotide Therapy Market Other Major And Innovative Companies

  • Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Avidity Biosciences Inc., Miragen Therapeutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V.

38. Global Oligonucleotide Therapy Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Oligonucleotide Therapy Market

40. Oligonucleotide Therapy Market High Potential Countries, Segments and Strategies

  • 40.1 Oligonucleotide Therapy Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Oligonucleotide Therapy Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Oligonucleotide Therapy Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer